Ballentine Partners LLC Acquires New Position in DexCom, Inc. (NASDAQ:DXCM)

Ballentine Partners LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,762 shares of the medical device company’s stock, valued at approximately $215,000.

Other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $25,000. Riverview Trust Co increased its stake in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares during the last quarter. RPg Family Wealth Advisory LLC purchased a new position in shares of DexCom during the 3rd quarter worth $57,000. Covestor Ltd boosted its position in shares of DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 335 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in shares of DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after purchasing an additional 265 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Trading Up 1.2 %

NASDAQ:DXCM opened at $88.75 on Friday. The stock has a fifty day moving average price of $79.50 and a 200 day moving average price of $77.35. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The firm has a market cap of $34.67 billion, a PE ratio of 53.14, a price-to-earnings-growth ratio of 2.23 and a beta of 1.12.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Royal Bank of Canada reduced their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Oppenheimer reduced their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Leerink Partners lowered their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Finally, Wells Fargo & Company upped their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $99.29.

Insider Activity

In other news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.